Good glycemic control tied to sarcopenia PREVENTION among diabetes patients
According to researchers from Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan, Dapagliflozin treatment in type 1 diabetes, non-obese individuals and the elderly results in loss of skeletal muscle mass. They said, during treatment, good glycemic control may prevent sarcopenia onset and progression.
This study entitled, “Changes in glycemic control and skeletal muscle mass indices after dapagliflozin treatment in individuals with type 1 diabetes mellitus” by Dr Yuta Yoshimura and colleagues is published in JDI, Journal of Diabetes Investigation.
There is a lack of data regarding effects of Dapagliflozin on skeletal muscle mass in type 1 diabetes patients. Some of the previous research has highlighted the effects of good glycemic control on skeletal muscle mass in such patients.
In the present study, researchers investigated changes in glycemic control and skeletal muscle mass with dapagliflozin in type 1 diabetes patients and the association between these changes.
The present study was a post-hoc analysis of a multicenter, open-label, non-randomized, prospective, interventional study. The participants were given 5mg/day of dapagliflozin for 4 weeks.
Researchers calculated Weight- and height-corrected appendicular skeletal muscle mass (ASM as indices of skeletal muscle mass. They did bioelectrical impedance analysis.
The key results of the study are:
- A total of 36 individuals were included.
- Following 4 weeks of dapagliflozin treatment, ASM/height decreased in the body mass index <23 group.
- There was a decrease in ASM / weight in all men who were aged >60 years.
- There was a negative correlation between the change in ASM / weight (%) and the change in glycated haemoglobin.
- There was a positive correlation between the change in ASM / height2 and the change in time within the glucose range of 70-180 mg/dL
The study had limitations like the study was based on short-term results with no control participants. The study had less number of participants which wasn’t enough to generalize the study’s findings.
They said,” We dint collect indicators of muscle function like grip strength and walking speed but our analysis provides valuable evidence of changes in the two skeletal muscle mass parameters.
They noted, “We found that ASM / height2, but not ASM / weight decreased after starting dapagliflozin medication.”
In the present study, we found no association between age and skeletal muscle mass in either men or women, they noted
As acknowledged, the RISING-STAR study is funded by AstraZeneca K.K. and Ono Pharmaceutical Co., Ltd.
Further reading:
https://pubmed.ncbi.nlm.nih.gov/37424302/
